<DOC>
	<DOCNO>NCT01669538</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study test whether medication call galantamine ( Brand Name : Razadyne ) help smoker quit whether reduces cognitive problem smoker experience quit attempt .</brief_summary>
	<brief_title>Effect Galantamine Short-term Abstinence</brief_title>
	<detailed_description>Galantamine , FDA-approved treatment Alzheimer 's disease , use treat cognitive impairment enhance acetylcholine inhibition enzyme , acetylcholinesterase . We propose randomized double-blind placebo-controlled study short-term ( 23 day ) treatment galantamine . Eighty chronic smoker complete validated procedure screen new medication . An equal number subject assign one two group : galantamine-ER placebo . Participants group take one capsule day follow procedure . This cross-over trial . For participant galantamine group , follow initial 1-week drug run-up phase ( 8mg daily galantamine-ER ) , medication dose increase 16mg daily galantamine-ER remainder study ( Day 23 ) . On Day 15 , smoker begin mandatory 24-hour abstinence period , follow programmed smoking lapse Day 16 . Smokers instruct abstain follow 7 day ( observed abstinence ) . Following completion study , participant offer standard smoke cessation treatment . On Days 0 ( Baseline ) , 14 , 16 , subject perform follow computer task : work memory task ( Visual/Spatial N-Back ) , sustain attention task ( Penn Continuous Performance Task [ PCPT-nl ] XO Reaction Time Task ) , recall memory task ( Word Recognition ) , interference control task ( Stroop test ) , response inhibition task ( Stop Signal Task ) . The primary outcome identify change behavioral performance subjective symptom follow two week treatment galantamine 24 hour abstinence , compare baseline . This study provide information role cholinergic system brief abstinence whether enhance acetylcholine reduces abstinence-induced cognitive symptom promote smoke relapse . Information obtain study may establish cognitive performance measure endophenotypes nicotine dependence .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>1 . Smokers 18 60 year age selfreport smoke least 10 cigarette ( menthol nonmenthol ) per day least last 6 month . 2 . Interest quit smoke next 2 6 month . 3 . Healthy determine Study Physician , base medical evaluation include medical history physical examination , psychiatric evaluation . 4 . Capable give write informed consent , include compliance requirement restriction list combined consent HIPAA form . 5 . Women childbearing potential must consent use medically accept method birth control participate study ( e.g. , condoms spermicide , oral contraceptive , Depoprovera injection , contraceptive patch , tubal ligation ) . 1 . Smoking behavior 1 . Use chew tobacco , snuff , and/or snus . 2 . Current enrollment smoking cessation program , use smoke cessation medication last month plan either next 2 month . 3 . Provide carbon monoxide ( CO ) breath sample read less 10 part per million ( ppm ) either Intake Baseline visit . 2 . Alcohol/Drugs 1 . Lifetime history substance abuse ( nicotine ) and/or currently receive treatment substance abuse ( e.g. , alcohol , opioids , cocaine , stimulant , PCP , benzodiazepine , studyprohibited medications/recreational drug ) determine selfreport phone screen and/or MINI Intake visit . 2 . Current alcohol consumption exceed 25 standard drinks/week past 6 month . 3 . Providing breath alcohol concentration ( BrAC ) read great equal 0.01 Intake , Baseline , Testing Days . 4 . A positive urine drug screen cocaine , amphetamine , methamphetamine , benzodiazepine , PCP , methadone , barbiturate , opiate Intake visit , Baseline visit , Testing day . 3 . Medical 1 . Women pregnant , plan pregnancy next 3 month , lactate ; female subject shall undergo urine pregnancy test Intake visit must agree write use approve method contraception . Following enrollment , pregnancy test conduct Baseline visit Testing day female subject childbearing potential . 2 . Diagnosis Alzheimer 's Disease dementia . 3 . Current treatment cancer diagnose cancer ( except basal cell carcinoma ) past 6 month . 4 . Liver/kidney failure , peptic ulcer disease , benign prostate hypertrophy . 5 . Asthma chronic obstructive pulmonary disease ( COPD ) . 6 . History ( last 6 month ) abnormal heart rhythm , tachycardia and/or cardiovascular disease ( stroke , angina , heart attack ) . These condition evaluate case case basis Study Physician/Health Care Provider . 7 . Serious unstable disease within past 6 month , determine Study Physician/Health Care Provider . 8 . Clinically significant abnormality within physical examination vital sign Medical Screen . Abnormalities assess Study Physician/Health Care Provider eligibility determine casebycase basis . 9 . Any impairment ( physical and/or neurological ) include visual impairment prevent cognitive task performance . 10 . Uncontrolled high blood pressure ( Systolic BP great 160 and/or Diastolic BP great 100 ) . 11 . Hearing impairment , significant hearing loss ( 20 % either ear ) , cochlear implant , bilateral hearing aid . 12 . History brain injury . 13 . History epilepsy seizure disorder . 14 . Color Blindness . 15 . Low borderline intellectual functioning determine receive score less 90 Shipley Institute Living Scale ( SILS ) correlate Wechsler Adult Intelligence ScaleRevised ( WAISR ) Estimated IQ Test ( administer Intake visit ) . 4 . Psychiatric Exclusions ( determine selfreport phone screen and/or MINI Intake visit ) 1 . Current diagnosis major depression . Persons history major depression , remission 6 month longer , eligible , provide exclude base medication ( ) . 2 . Suicide risk score MINI great 0 . 3 . History current diagnosis schizophrenia , psychosis , and/or bipolar disorder . 4 . Current past hypomanic/manic episode . 5 . Current history diagnosis AttentionDeficit/Hyperactivity Disorder ( ADHD ) . 5 . Medication 1 . Current use , recent discontinuation ( within last month ) form smoke cessation medication ( i.e. , Zyban , Wellbutrin , Wellbutrin SR , Chantix , nicotine replacement therapy ) . 2 . Current use recent discontinuation ( within last 60 day ) follow : Antianxiety panic disorder medication . Antipsychotic medication . Moodstabilizers ( e.g. , Lithium , Lamictal/lamotrigine , Neurontin/gabapentin , Topamax/topiramate , valproic acid , Tegretol/carbamazepine ) . Antidepressants ( e.g. , Wellbutrin , MAOIs , SSRIs , tricyclic antidepressant ) . Prescription stimulant ( e.g. , Provigil , Ritalin , Adderall ) . Systemic Steroids ( e.g. , Prednisone ) . Alzheimer 's disease medication ( e.g. , Acetylcholinesterase inhibitor ( ACIs ) , Aricept/donepezil , Exelon/rivastigmine , Tacrine , memantine ) . Parkinson 's disease medication ( e.g. , Cogentin/benztropine ) . Irritable bowel syndrome medication ( e.g. , Dicylomine/Bentyl ) . Heart medication ( e.g. , quinidine Procardia/nifedipine ) . Peptic ulcer disease medication ( e.g , Zantac/ranitidine ) . Muscle relaxant ( e.g. , Soma/carisoprodol , Anectine/succinylcholine ) . Antifungal medication ( e.g. , Nizoral/ketoconazole ) . Antiseizure medication ( e.g. , Ativan , Banzel , Carbatrol , Dilantin , Lamictal , Gabitril , Lyrica , Neurontin , Tegretol , Topamax ) . COPD medication ( e.g. , Atrovent/Ipratropium Bromide ) . Urinary retention medication ( e.g. , Duvoid/bethanechol , Proscar/finasteride , Avodart/dutasteride , Dibenzyline/phenoxybenzamine , Regitine/phentolamine ) . Eye medication ( e.g. , Atropine ) . 3 . Daily use following : Opiatecontaining medication chronic pain ( Duragesic/fentanyl patch , Percocet , Oxycontin ) . Medication asthma ( albuterol , Serevent , Combivent , Advair , Flovent , Azmacort , Symbicort ) . 4 . Known drug allergy study medication . Subjects instruct refrain use study prohibit drugs/medications ( recreational prescription ) throughout participation study . After final eligibility confirm , subject report take contraindicate medication ( ) course study period may remain eligible Study Physician and/or Principal Investigator determines contraindicate medication ( ) do/did impact study design , data quality , and/or subject safety/welfare . Subjects permit take necessary prescription medication include within exclusion list study . 6 . General exclusion 1 . Current , anticipate , pending enrollment another research program next 23 month could potentially affect subject safety and/or study data/design determine Principal Investigator and/or Study Physician . 2 . Not plan live area next two month . 3 . Any medical condition , illness , disorder , concomitant medication could compromise participant safety treatment , determine Principal Investigator and/or Study Physician . 4 . Inability provide inform consent complete study task determine Principal Investigator . 5 . Completion neurocognitive assessment and/or use study medication ( ) CIRNA past 6months could influence performance study task determine Principal Investigator . 6 . Not able effectively communicate English ( read , write , speak ) . 7 . Missing 2 consecutive session , 3 session medication period . 8 . Missing 2 consecutive dos medication period . 9 . Missing 3 dos throughout medication period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Galantamine</keyword>
	<keyword>Nicotine Bitartrate</keyword>
	<keyword>Nicotine Tartrate</keyword>
	<keyword>Nicotine dependence</keyword>
	<keyword>Tobacco Dependence</keyword>
</DOC>